Also found in: Medical.
FGFRFibroblast Growth Factor Receptor
FGFRFresh Gas Flow Rate (anesthesia)
References in periodicals archive ?
FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis and tumor cell survival.
Compared to FGFR gene mutation and translocation, gene amplification of FGFR is most well studied.
Entidades craneoestenoticas alelicas de los genes FGFR.
Dado que el LPH aislado, es una alteracion congenita compleja de origen multifactorial, en la mayoria de los casos, esta causado por la interaccion entre el medio ambiente y varios genes involucrados con la via de senalizacion FGF, incluyendo FGFR1, FGFR2, y FGFR 3, FGF2, FGF3, FGF4, FGF7, FGF8, FGF9, FGF10 y FGF18, NUDT6, FCTBR, y PAX38, entre otros que podrian estar relacionados con esta via de senalizacion.
It is well established that the signals evoked by FGF family members are converted by four major FGFRs, namely FGFR1 to FGFR4, to exert myriad biological effects on embryonic development and homeostasis in the adult for a wide range of tissues (14).
Las glandulas paratiroides, expresan FGFR y Klotho, pero que FGF23 estimule o inhiba la secrecion de PTH es incierto.
For each gene encoding an FGF or FGFR, we extracted tag SNPs within 10 kb upstream of the transcriptional start site and 10 kb downstream of the transcriptional stop site.
The most commonly made distinction in FGFR isoforms are the IIIb and IIIc isoforms, differing by alternative splicing of a pair of exons, and possessing different FGF affinities (Groth and Lardelli, 2002).
The antibodies that are the subject of the announcement are directed against a human growth factor receptor, FGFR 3 (fibroblast growth factor receptor 3), and were generated by MorphoSys using their proprietary HuCAL technology within the existing agreement between the two companies.
BridgeBio Pharma, a clinical- stage biotech company, has licensed infigratinib (BGJ398), a selective inhibitor of the tyrosine kinase receptor FGFR and a late-stage oncology drug, from Novartis, it was reported yesterday.
ArQule announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma.
FGF-regulated miRNAs and their targets will be identified starting from a combination of miRNA and mRNA profiling of RNA samples from epidermis of control and FGFR mutant mice at different stages of postnatal development and of tumors.